StockNews.com Initiates Coverage on vTv Therapeutics, Issues Sell Rating StockNews.com has launched coverage on vTv Therapeutics, assigning the biotechnology company a "sell" rating. The firm’s lead candidate, cadisegliatin, is in Phase III trials for diabetes treatment. Alliance Global Partners, however, has issued a contrasting "buy" rating and a $35.00 price target for the stock.1